In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.
|Webcasts|January 30, 2020
Benchmark Your Clinical Development Plans and Drive Better Clinical Strategy
Author(s)IQVIA
Enter a new era of clinical development planning. Use the power of “big data” and machine learning to generate more accurate plans that embrace uncertainty. Learn how to improve your development planning strategy while reducing trial costs and durations. Live: Thursday, Jan. 30, 2020 at 11am EST | 10am PST | 4pm GMT | 5pm CET On demand available after airing until Jan. 30, 2021. Register free
Register free:
Event Overview:
With larger pipelines, and a complex clinical trial landscape, it’s difficult for manufacturers to build a single development plan, let alone try to optimize it. Benchmark data has historically been limited and manufacturers rely heavily on their own prior experiences. But the growth of “big data” and machine learning has provided new ways to optimize clinical development strategy.
In this webinar, we’ll discuss how “big” clinical and commercial data feeds, as well as powerful machine learning algorithms have fundamentally changed clinical development planning. We’ll discuss case studies showing the impact these new approaches have had in the industry. And we’ll show how a new breed of software tools can help internal stakeholders make better decisions more quickly.
Key Take-aways:
Learn how to benchmark your clinical development plans against a new industry database of development costs and timing
Improve the accuracy of your clinical development plan, and provide additional alternatives to your leadership team for more informed decision-making
Compare what-if scenarios and conduct ranges analysis to fully understand the key drivers for development plan costs and timing
Speakers: Rick Johnston, Ph.D., Senior Software Solutions Lead, IQVIA
David Wolter, MBA, VP Consulting Services, IQVIA
Time and date: Thursday, Jan. 30, 2020 at 11am EST | 10am PST | 4pm GMT | 5pm CET
On demand available after airing until Jan. 30, 2021.
Sponsor: IQVIA
Register free:
Related to this article
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.
ACT Brief: Community Research Financing Gaps, Neuroscience Endpoint Data, and Teva’s Biosimilar Deal
In today’s ACT Brief, we examine why community research needs lasting financing and infrastructure, how electronic outcome tools can strengthen neuroscience endpoints, and how Teva is licensing two biosimilars from Samsung Bioepis.
Neuroscience trials struggle to show benefit because symptoms are subjective and variable, and eCOA strengthens dossiers by standardizing ClinRO administration, capturing outcomes in real time to reduce recall bias, and adding patient and caregiver perspectives that clinician scales miss.
Community participation gaps look less like a question of patient willingness and more like a financing and infrastructure problem that no single bill has yet solved.
In today’s ACT Brief, we examine what changes when AI is embedded across clinical operations, why faster trial data isn’t yet producing faster decisions, and how FDA granted accelerated approval to a therapy for a rare airway disease.
Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
Trending on Applied Clinical Trials Online
1
Comparing OpenAI and Mistral on Clinical Trial Matching
2
Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health
3
From Complexity to Endpoint Meaningfulness: Addressing Key Neuroscience Trial Challenges with eCOA
4
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
5